CEL-SCI CORP
NYSE: CVM (Cel-Sci Corporation)
Last update: yesterday, 11:29PM1.21
-0.26 (-17.69%)
| Previous Close | 1.47 |
| Volume | 879,800 |
| Avg. Volume (3M) | 218,748 |
| Market Cap | 21,282,676 |
| Price / Book | 2.22 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2026 |
| Diluted EPS (TTM) | -1.59 |
| Total Debt/Equity (MRQ) | 72.10% |
| Current Ratio (MRQ) | 1.48 |
| Operating Cash Flow (TTM) | -16.75 M |
| Levered Free Cash Flow (TTM) | -8.91 M |
| Return on Assets (TTM) | -66.82% |
| Return on Equity (TTM) | -252.53% |
AIStockmoo Score
| Value 30% | -3.8 |
| Earns below its cost of capital. Returns on capital falling. info | |
| Low debt. Weak profitability. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -4.4 |
| Downtrend over the past year. Far below its 52-week high. info | |
| In a downtrend, but its moving averages have flattened. It is close to them. It broke below them on high volume. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | -0.5 |
| Institutions net -0.25% of shares in their latest 13F filings: 22 holders increased, 8 decreased (quarter to 30 Sep 2026). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have risen every year. Made a loss in recent years. info | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is near support. info | |
| Final Score | -3.67 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cel-Sci Corporation | - | - |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| CVM | 21 M | - | - | 2.22 | -3.7 |
| CYBN | 359 M | - | - | - | 0.0 |
| NRXS | 60 M | - | - | 18.58 | -1.2 |
| NHWK | 20 M | - | - | 0.260 | 0.0 |
| AEON | 10 M | - | - | - | -3.3 |
| TOVX | 6 M | - | 0.099 | 0.610 | -2.7 |
Select this tab to load the latest available analysis.
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 3.71% |
| % Held by Institutions | 14.60% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mai Capital Management | 30 Sep 2026 | 109,280 |
No data within this time range.
Institutions
Institutional ownership: 12.94%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 22 | 196,419 |
| Decreased | 8 | 208,017 |
| New | 7 | 29,620 |
| Sold out | 3 | 62,567 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2026 | Yahoo Finance |
CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
VIENNA, Va., November 20, 2026--CEL-SCI’s Multikine receives Saudi FDA NADR Designation, accelerating potential commercial launch. |
| 10 Nov 2026 | Yahoo Finance |
CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
VIENNA, Va., November 10, 2026--CEL-SCI’s Dr. Eyal Talor receives second international keynote invitation on Multikine head and neck cancer research. |
| 29 Oct 2026 | Yahoo Finance |
CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis
CEL-SCI Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company’s completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy for head and neck cancer. The findings were… |
| 26 Oct 2026 | Yahoo Finance |
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
VIENNA, Va,, October 26, 2026--CEL-SCI presents Phase 3 Multikine data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival. |
| 15 Sep 2026 | Yahoo Finance |
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology. |
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |